Compass Pathways and a Non‑Profit Vie for First Psychedelic Drug Approval
Compass Pathways is seen as a frontrunner, but a non‑profit organization is closing in on its own psychedelic approval effort.
Trend: The race to bring the first psychedelic drug to market is intensifying as both a biotech firm and a non‑profit organization advance their development pipelines.
Compass Pathways has been identified as a leading contender for achieving the inaugural regulatory approval of a psychedelic therapy.
At the same time, a non‑profit organization is making significant progress with its own psychedelic efforts, suggesting a tight competition for the milestone.
The eventual winner could set precedents for how psychedelic medicines are evaluated and commercialized.
How the first approval unfolds may define the future trajectory of psychedelic therapeutics.
